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ABSTRACT 
 
Objective: This randomized, double-blind, placebo-controlled crossover study assessed the 
efficacy of topical tocopherol acetate compared with placebo in easing oral discomfort in 
patients with reticular oral lichen planus (ROLP). 
Materials and Methods:  34 patients with clinically diagnosed and histologically confirmed 
ROLP were randomly assigned to two groups, which received first one of two treatments 
(treatment 1 or 2) for a month, then the other (treatment 2 or 1) for another month, with a 
two-week washout between them. One treatment contained tocopherol acetate, the other only 
liquid paraffin. The primary outcome was less discomfort, measured on a visual analog scale 
(VAS). Secondary outcomes were: length of striae measured and photographed at each 
follow-up; surface area of lesions; and a modified Thongprasom score. 
Results: No statistically significant differences emerged between the two treatments (1 vs 2) 
in terms of VAS scores (P>0.05; 0.8624), or length of striae (P=0.0883). Significant 
differences were seen for surface area of lesions (P<0.05, P=0.0045), and modified 
Thongprasom scores (P=0.0052). 
Conclusion: The two treatments differed only in terms of the surface area of the lesions and 
Thongprasom scores, not in VAS scores for discomfort or the length of patients’ striae. 
Topical tocopherol proved effective in the treatment of ROLP. 
 
 
Keywords: oral lichen planus, tocopherol, reticular oral lichen planus, ImageJ, Thongprasom 
scale 
 
INTRODUCTION 
Oral lichen planus (OLP) is a chronic inflammatory disease affecting the stratified squamous 
epithelium (Eisen D et al.). It occurs quite frequently in the general population, with a 
prevalence of 1.27% and a male/female ratio of 2:3. It mainly involves adults from 30 to 60 
years old (Lodi G et al.). 
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The etiology of OLP has yet to be fully clarified, but various hypotheses have been advanced, 
including the idea of an autoimmune condition: processing of the antigen by the dendritic 
cells (Langerhans cells) and its presentation to the T lymphocytes leads to activation of the 
CD4+ and CD8+ T cells and apoptosis of the basal cells. Some authors suggest a correlation 
with infectious factors such as HCV, HSV2, HIV, Candida, and Treponema pallidum, which 
prompt activation of the lymphocytes, which thus become cytotoxic for the keratinocytes of 
the basal layer. These infectious factors thus allow the disease to become manifest 
(Roopashree MR et al, Romero MA et al, Lodi G. et al.). 
 
Psychosomatic and emotional factors also seem to play an important part in the onset of OLP. 
Its clinical manifestations often develop in subjects who have been under severe stress. This 
has been confirmed by epidemiological evidence of patients with OLP having high levels of 
anxiety and depression, and a greater vulnerability to psychological disorders (Soto Araya M 
et al.). 
 
The lesions may appear clinically in a reticular pattern or form papules or plaques, or it may 
be described as atrophic and ulcerative, or bullous (erosive) (Lodi G et al.).  
 
In 2003, van der Meij EH, van der Waal suggested a type of classification which reconsiders 
the classification WHO of 1978 (WHO 1978), on the basis of a scarce correspondence 
between the clinical suspicion of lichen and the histopathological observation of the biopsy 
(Van Der Meji & Van Der Waal, 2003). 
 
The reticular form usually causes no symptoms (Neville BW et al), but sometimes it can 
cause severe discomfort to the patient, mainly when the tongue touches the lesions or the 
food bolus passes in the mouth. As stated by some authors (Yang H. et al.), the treatment of 
OLP is symptomatic, so the patients decided to participate to the study because they felt some 
kind of discomfort. Occasionally, however, patients may develop Candida superinfections, 
which cause a burning sensation in the oral mucosa, making anti-fungal therapy necessary in 
such cases. (Neville BW et al.). 
 
On the other hand, erosive OLP gives rise to a distinct set of symptoms. In recent decades, 
various treatments have been attempted with a view to reducing the lesions and easing the 
associated pain, but no definitive treatment has been identified to date (Lodi G et al.), partly 
because of the refractory nature of this disease (Lozada-Nur F & Miranda C; Lodi G et al.; 
Eisen D et al.). 
 
Topical corticosteroids have been amply used to treat vesicular-erosive diseases of the oral 
mucosa (including OLP) in an effort to reduce the related pain and inflammation (Neville 
BW et al.; Gonzalez-Moles MA & Scully C.). A certain utility has been demonstrated for 
some of these preparations, when applied directly to the lesions. They are beneficial in 
controlling the disease because of their anti-inflammatory effects and immunomodulation 
properties, making them capable of suppressing T cell function (Yoke PC et al.). Systemic 
therapy is necessary in some cases, and steroid dosage must be tailored to individual patients 
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depending on the nature of their lesions, the patients’ weight, and their response to the 
treatment (Al-Hashimi I et al.). 
 
Topical or systemic tacrolimus has proved effective, but this drug is potentially carcinogenic 
(Lozada-Nur FI & Sroussi HY). 
 
For this type of disease, six-monthly follow-up is mandatory in order to monitor the patient’s 
condition adequately (Epstein J.B. et al.) 
 
An essential vitamin vital to human nutrition, tocopherol is a powerful liposoluble 
antioxidant contained in many plants. Vitamin E plays a fundamental part as an antioxidant 
factor in preventing oxidation of polyunsaturated fatty acids, a key event in the process of 
lipid peroxidation. (Kim SK et al., Heidari R et al, Niki E.)  Since the onset of lipid 
peroxidation can give rise to profound changes in the cell membranes, vitamin E is 
acknowledged an important role in keeping these structures intact (Brigelius-Flohe R & 
Traber MG; Dutta A & Dutta SK). More detailed studies have demonstrated that tocopherol 
interacts directly with protein phosphatase 2A (PP-2A), which subsequently 
dephosphorylates various cell substrates, including some isoforms of protein-kinase C (PKC). 
Thanks to this mechanism, tocopherol can also behave as an antiproliferative agent against 
tumor cells. The existence of the universal mechanism of alpha-TPh cytoprotective action 
that does not depend on the nature of apoptogenes and realized on the general for the majority 
of them stage of the cells death induction is stated. (Petrova GV et al., Neuzil J et al.) 
Tocopherol has been used in the past for the prevention and treatment of oral mucositis in 
adults (Wadleigh RG et al.; Lopez I et al.) and children (El-Housseiny AA. et al.). In most 
studies, the role of vitamin E in maintaining and repairing the cell membranes has been well 
documented (Khurana H. et al.).  
 
The present double-blind, randomized, placebo-controlled crossover study was devised to 
assess the efficacy of topical tocopherol acetate in improving the lesions and oral discomfort 
of patients suffering from reticular oral lichen planus (ROLP), comparing it with the results 
achievable by administering placebo. The term discomfort was used referring to “tactile 
discomfort”, when the tongue impacted the lesion on the mucosa. 
 
MATERIALS AND METHODS  
The study involved patients with a clinical diagnosis of ROLP, histologically confirmed as 
established by some authors (Al-Hashimi I et al.), all routinely followed up at the Dental 
Clinic of Padua University Hospital (Ambulatorio di Medicina e Patologia Orale).  
Patients were enrolled according to the following criteria: 
 
Inclusion criteria  
• Patients with lesions more than a year; 
• patients who, after being informed in adequate detail, agreed to be examined and 
assessed at each follow-up; 
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• patients at least 18 years old and in full possession of their mental faculties; 
• patients with ascertained oral lesions, but possibly also with cutaneous or genital 
lesions.  
• Patients experiencing “tactile discomfort”, when the tongue impacted the lesion on the 
mucosa or the food bolus touches the lesions 
 
Exclusion criteria  
• patients with a clinical or histological diagnosis of erosive, bullous, or plaque-forming 
oral lichen planus; 
• patients under treatment with immunomodulatory drugs; 
• patients who might have previously received conventional treatments (in the previous 
two weeks); 
• patients refusing to give their informed consent to the trial; 
• patients who might have previously taken antifungal drugs for the prevention or 
treatment of Candida superinfection (in the previous two weeks); 
• Patients with concomitant oral pathologies (e.g. aphtosis). 
 
Patients were considered independently from the localization of the lesions. 
The detailed medical record was collected, particularly the eventual presence of other 
autoimmune and dermatological pathologies. Thus, it was also taken into account the fact to 
be a smoker or not. 
 
Patients were divided into two groups (A or B), each of which was administered two different 
treatments sequentially (group A: tocopherol then placebo; group B: placebo then 
tocopherol). Patients were randomized to either group based on a list prepared with an 
appropriate software (SAS 9.2 for Windows, SAS Institute Inc., Cary, NC, USA). The 
treatment sequences for each patient were anonymized and sealed in envelopes marked with 
patient identification numbers, based on their order of enrolment in the study (patient 1, 2, 3, 
etc.) and the envelopes were only opened after a patient had been included in the study. The 
complete randomization list and the correspondence between the anonymous codes and the 
treatments was kept by a person uninvolved in the trial. Both groups were given their first 
treatment for one month, then waited a two-week interval (washout period) before starting the 
other. One treatment consisted of a gelly formulation of tocopherol acetate, the other 
(placebo) of a gelly formulation of Vaseline BFR070 FU (paraffinum liquidum) and its 
composition was identical to that of the other product except for the absence of tocopherol 
(Picture 1). The supplier identified the two products with two numerical codes (347/2 and 
348/2) and the product corresponding to each code was not known to the experimenters or the 
patients. Group A received the treatment in the sequence 347/2  348/2, and group B vice 
versa. 
 
Patients were instructed to apply the gel using the applicator given by the supplier in the 
entire inner part of the oral cavity, but more carefully in the sites indicated by us as most 
affected by the reticular lesions; this practice had to be made for three times per day, daily 
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until the next visit. Patients were also told neither to eat nor to drink in the thirty minutes 
following the application of the product. 
 
 The request for approval by the ethics committee was sent in August 2012, the final approval 
was obtained in December 2012 (Prot.n.2769P), the patient recruitment started in April 2013. 
For each patient, the study lasted a total of 10 weeks. Patients received no compensation for 
their participation in the study.  
 
Assessment parameters  
Patients were examined four times in all: at the baseline; after the first treatment (lasting four 
weeks); at the end of the washout period (after another two weeks); and at the end of the 
second treatment (lasting another four weeks). The primary outcome of interest was an 
improvement in patients’ discomfort, measured using a visual analogue scale (on a range 
from 0 to 10) (Wu Y et al.). Any reported unpleasant sensation, pain, burning or itching was 
recorded, and contributed to defining the overall level of discomfort and the quality of 
disease control on the VAS (scores ranging from 0 to 10). A record was also kept of anything 
patients reported concerning their perception of flavours and any changes their condition had 
prompted in their diet and digestion. As secondary outcomes, we examined the trend of the 
reticular lesions. This was assessed by measuring the length and surface area of the lesions 
with a gauge, taking photographs at the time of each visit, and comparing them with the 
ImageJ software (Wayne Rasband, US National Institute of Health, Bethesda) This program 
standardizes images on the basis of a measure of known length, and has been used by several 
authors for the purpose digital image analysis). (Kerner S. et al, Lops D et al.). Eight standard 
photographs were taken: one frontal, one direct of each vestibular portion, two supported by 
the lateral mirrors of the attached gingiva and vestibular fornixes, another two under indirect 
view of the palate and floor of the mouth, and one of the tongue (Picture 2, 3, 4). Each 
photograph was also adjusted in relation to the measurements obtained clinically at each visit. 
In addition, a scale based on the clinical criteria developed by Thongprasom was adopted, 
generating a score where: 0= no lesions; 1 = white striae with no signs of erythema; 2 = white 
striae with areas of atrophy <1 cm2; 3 = white striae with areas of atrophy >1 cm2; 4 = white 
striae with areas of erosion <1 cm2; 5 = white striae with areas of erosion >1 cm2 
(Thongprasom K et al.) This score was modified for the purposes of the present study, 
considering only grades 0 to 3, because any presence of erosive lesions was one of our 
exclusion criteria.  
 
Statistical analyses  
The numerosity of the sample was based on the expectation of a difference between the two 
treatments of one point on the VAS (primary variable) with a standard deviation of 2 (the 
standard deviation considered was for within-subject differences). The number of patients 
with ROLP needed for this percentage to be significant was estimated to be 34, with a power 
of 80% and an α of 5% bilaterally. The Shapiro-Wilk test was used to check the normality of 
the quantitative data. 
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The patients’ baseline characteristics are presented by treatment sequence (12/21). 
Categorical variables were presented as counts and percentages in each sequence, and 
compared with the chi-square or Fisher’s exact tests. For quantitative variables, median, 
minimum and maximum values were reported and analyzed with Wilcoxon’s rank sum test 
because the distribution was not normal. 
 
Results for the outcome variables are presented by treatment group, reporting the median, 
minimum and maximum values at the baseline and at the end of each treatment, and 
compared with a mixed-model analysis of covariance on the rank-transformed values, 
considering the baseline value as the covariate and the period and treatment as the factors. 
The level of significance was set at 5%. The analyses were performed with the SAS 9.2 
software (SAS Institute Inc., Cary, NC, USA) for Windows. 
 
 
RESULTS  
Of the 34 patients enrolled, 33 completed the study (one was uncooperative and failed to do 
it, so it was considered drop-out); of these patients, 22 were women, and 11 were men. In this 
sample, 32 patients were non-smokers and one female patient smoked. Four patients had a 
history of hepatitis (two were HBV-positive, and two HCV-positive). Seven patients had a 
positive clinical history of dermatological diseases such as seborrhoea, androgenetic hair loss, 
alopecia, contact dermatitis, eczema, and erythema. The localization of the lesions was 
posterior buccal mucosa, bilaterally; the back, the lateral margins and the belly of the tongue, 
the gums, the palate (Neville BW et al.) and the lips (Romero MA et al.). Three of our 
patients (9.09%) present also vulvo-vaginal lesions. 
 
The results are summarized in Tables 1 and 2. 
 
Baseline characteristics of the patients by sequence of randomization were presented at table 
1. 
Median (min-max) for VAS score was 1.85 (0.10-7.65) for all patients, 2.40 (0.10-7.65) for 
AB sequence and 1.73 (0.20-7.00) for BA sequence with p-value =0.6653. 
 
Median (min-max) of Thongprasom score was 1(0-3) for all patients, 2(0-3) for AB sequence 
and 1(0-3) for BA sequence with p-value =0.1159;  
 
Median (min-max) of lesion area (mm²) was 216.00 (0.00-1285.03) for all patients, 216.00 
(0.00-989.60) for AB sequence and 283.80 (0.00-1285.03) for BA sequence with p-value = 
0.4073. 
 
Furthermore median (min-max) Lesion length (mm) was 35.0 (0.0-98.0) for all patients, 18.0 
(0.0-75.0) for AB sequence and 49.5 (0.0-98.0) for BA sequence with p-value = 0.0110. 
The analysis of covariance on outcomes for the treatment at baseline and follow-up for the 
treatment A and at baseline and follow-up for the treatment B is presented at table 2.  
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Median (min-max) of VAS score at baseline of treatment A was 1.70 (0.10-7.65) , at follow-
up of treatment A was 1.75 (0.00-8.80) , while at baseline of treatment B was 2.45 (0.10-
7.70)  and at follow-up of treatment B was 2.28 (0.05-7.80) ,with p-value = 0.8624. 
 
Median (min-max) of Thongprasom scale at baseline of treatment A was 2 (0-3), at follow-up 
of treatment A was 1 (0-3), while at baseline of treatment B was 1 (0-3) and at follow-up of 
treatment B was 1 (0-3), with p-value = 0.0052. 
 
Median (min-max) of lesion area (mm²) at baseline of treatment A was 265.7 (0-1208.9), at 
follow-up of treatment A was 122.7 (0-540.3), while at baseline of treatment B was 124.0 
(0.0-1285.0) and at follow-up of treatment B was 231.8 (0.0-1497.6) with p-value = 0.0045. 
 
Median (min-max) of lesion length (mm) at baseline of treatment A was 35 (0-141), at 
follow-up of treatment A was 29 (0-99), while at baseline of treatment B was36 (0-98) and at 
follow-up of treatment B was 40 (0-112) with p-value = 0.0883 . 
 
None of the patients reported any side-effects of either of the two treatments. Seven patients 
reported finding it difficult to apply the products, and one of them judged them virtually 
impossible to apply. 
 
DISCUSSION  
We presented a study evaluating the efficacy of topical tocopherol acetate compared with 
placebo in easing oral discomfort in patients with reticular oral lichen planus (ROLP).  
There are some studies in the literature (Gastaldi G et al., Petruzzi M et al., Petruzzi M. et al.) 
in which is described the use of tocopherol oil in OLP patients. Other studies state that any 
specific benefits of antioxidant micronutrients (retinol, alpha-tocopherol, zeaxanthin/lutein 
and cryptoxanthin, lycopene, alpha-carotene and beta-carotene) cannot be claimed for this 
inflammatory disorder (Nagao T. et al.).  
 
The hypothesis was that this substance could improve disease control and reduce the related 
discomfort. The findings emerging from the study  appeared to differ, depending on the 
variables taken into consideration. 
 
As for the results of the present study, there was a reduction of one point on the VAS, but this 
difference did not appear to be statistically significant (P>0.05; 0.8624). It is important to 
bear in mind, however, that this is a somewhat subjective parameter, and the scores identified 
on the VAS by our patients were all very low. The VAS was used in the present study to 
quantify the patients’ level of discomfort, where the term "discomfort" was used to mean the 
“tactile discomfort”, when the tongue impacted the lesion on the mucosa, from mild tingling 
to real pain. 
 
The variations in the length of the lesions measured directly, with the aid of a gauge, in the 
patients’ oral cavity were not statistically significant (P = 0.0883). To document the 
dimensional changes in the lesions objectively at each follow-up visit, we obtained eight 
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digital photographs (Lozada-Nur F et Miranda C; Aguirre JM et al.; Radfar . et al.; van der 
Meij EHI & van der Waal I) and processed them with a software (ImageJ) already amply 
used in other medical fields (Alman AC et al., Grbatinić I & Milošević NT). Based on the 
lengths actually measured and adjusted to each different photograph, we calculated the 
surface area of the main lesions and compared the findings at the various follow-up visits. 
The analysis of these results revealed a statistically significant reduction in the dimensions of 
the lesions (P = 0.0045), and a greater reduction for tocopherol than for placebo. The 
drawback of this approach lies in that it gives areas based on two dimensions, not three; the 
advantage lies in that it considers a surface area rather than just a linear measurement (some 
lesions may be long and narrow, others broader and shorter), so it presumably affords a fairly 
good estimate of the boundaries of such areas. 
 
The analysis of the modified Thongprasom scores (Salazar-Sànchez N et al.; Nolan A et al.), 
revealed a statistically significant difference (P = 0.0052) between the two treatments. 
None of the patients reported any adverse effects during or after the administration of either 
of the treatments. 
 
Judging from their VAS scores, 20 patients (60.60%) improved with the tocopherol 
treatment, while 18 (54.54%) improved with the placebo. When the length of the lesions was 
measured, 18 patients (54.54%) improved with the tocopherol treatment, and 18 (54.54%) 
with the placebo. The data obtained on the surface area of the lesions indicated that 26 
patients (78.78%) benefited from the tocopherol preparation and 14 (42.42%) from the 
placebo. Finally, when we considered the modified Thongprasom scale, it emerged that 12 
patients (36.36%) experienced an improvement with tocopherol and only 2 (6.06%) with the 
placebo. 
 
These figures point to a clearly evident placebo effect (Salazar-Sànchez N et al.) starting with 
the first treatment. This result would confirm the psychosomatic and emotional aspects 
associated with OLP (Soto Araya M et al.). This may relate partly to the fact that patients 
were followed up with more frequent clinical examinations and took part in a strict protocol, 
possibly inducing them to report an improved disease control irrespective of the type of 
treatment administered. 
 
Seven patients (21.21%) complained of having difficulty with the application of the two 
products. This finding points to the utility of adopting a two-point scale (Nolan A et al.) on 
which patients are asked to comment on the ease of application of a product being tested (1 = 
easy to apply; 0 = difficult to apply).  
 
As for the post-treatment follow-up beyond the experimental phase, our patients were seen 
again every three or four months in the more severe cases, and every six months in the cases 
most responsive to the treatment (Yoke PC. et al.) 
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Two patients included in the study were HCV positive, whereas other two patients were HBV 
positive. HCV and HBV may create occurences similar to the lichen (Lodi et al. 2004, 
Romero et al. 2002). In our study the patients alrealdy had clinical and histological diagnosis 
of lichen, since they all had already been biopsied. 
 
CONCLUSION 
This study aimed to test the efficacy of vitamin E in the treatment of ROLP, with a view to 
exploiting its antioxidant effect in actively preventing the oxidation of polyunsaturated fatty 
acids and developing the process of lipid peroxidation. 
Surprisingly, statistically significant differences (P<0.05) between the two treatments adopted 
in the two successive periods only emerged in terms of the surface area of the lesions and the 
score on the Thongprasom scale. There was no evidence of any statistically significant 
differences (P>0.05) when we compared the VAS scores for discomfort or the length of the 
lesions in the oral cavity. 
Topical tocopherol thus proved effective in reducing the dimension of the lesions in the 
course of OLP, but it does not improve VAS score. 
 
Figure 1: tocopherol or placebo applicator 
Figure 2, 3, 4: clinical features of ROLP 
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Statistical Analysis 
Shapiro-Wilk test was used to check the normality of the quantitative data. 
The patients’ characteristics at baseline are presented by sequence of treatment (AB/BA). 
Categorical variables were presented as count and percentage in each sequence and compared 
with chi-square or Fisher’s exact test, for quantitative variables median, minimum and 
maximum were reported and analyzed with Wilcoxon rank sum test since the distribution was 
not normal. 
Results for the outcome variables were presented by treatment group reporting the median, 
minimum and maximum at baseline and end-of-treatment and compared with a mixed model 
analysis of covariance on the values rank-transformed and considering the baseline value as 
covariate and the factors period and treatment. 
The level of significance was set at the 5% value. The analyses were performed with SAS 9.2 
(SAS Institute Inc., Cary, NC, USA) for Windows. 
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Table 1 – Baseline characteristics of the patients by sequence of randomization. 
 All patients (n=33) Sequence p-value
 AB (n=17) BA (n=16) 
Gender F n (%) 22 (66.7) 11 (64.7) 11 (68.8) 0.8055 
Smoke n (%) 1 (3.0) 0 (0.0) 1 (6.3) 0.4848
Diseases    
 Hepatitis n (%) 4 (12.1) 2 (11.8) 2 (12.5) 1.0000 
 Stress n (%) 8 (24.2) 6 (35.3) 2 (12.5) 0.2245 
 Autoimmune n (%) 5 (15.2) 3 (17.7) 2 (12.5) 1.0000 
 Dermatologic n (%) 7 (21.2) 5 (29.4) 2 (12.5) 0.3983 
Thongprasom scale Median (min-max) 1 (0-3) 2 (0-3) 1 (0-3) 0.1159 
VAS Median (min-max) 1.85 (0.10-7.65) 2.40 (0.10-7.65) 1.73 (0.20-7.00) 0.6653 
Lesion area (mm²) Median (min-max) 216.00 (0.00-1285.03) 216.00 (0.00-989.60) 283.80 (0.00-1285.03) 0.4073 
Lesion length (mm) Median (min-max)  35.0  (0.0-98.0) 18.0 (0.0-75.0) 49.5 (0.0-98.0) 0.0110 
 
Table 2 – Analysis of covariance on outcomes. 
 Treatment p-value
 A B  
 Baseline Follow-up Baseline Follow-up 
Thongprasom scale Median (min-max) 2 (0-3) 1 (0-3) 1 (0-3) 1 (0-3) 0.0052 
VAS Median (min-max) 1.70 (0.10-7.65) 1.75 (0.00-8.80) 2.45 (0.10-7.70) 2.28 (0.05-7.80) 0.8624 
Lesion area (mm²) Median (min-max) 265.7 (0-1208.9) 122.7 (0-540.3) 124.0 (0.0-1285.0) 231.8 (0.0-1497.6) 0.0045 
Lesion length (mm) Median (min-max) 35 (0-141) 29 (0-99) 36 (0-98) 40 (0-112) 0.0883 
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